IP Library › Granted Patent US 10,138,292
Granted Patent B2
US 10,138,292 · App. 13/328,156 · Granted Nov 27, 2018

Cell culture medium

Inventors: Karl Tryggvason (Djursholm, SE); Sergey Rodin (Stockholm, SE)
Assignee: BIOLAMINA AB
C07K14/78C12N5/0606C12N5/0696C12N2501/602C12N2501/603C12N2501/605C12N2501/608C12N2510/00C12N2533/52Y10T428/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,138,292
App. No.
13/328,156
Granted
Nov 27, 2018
Kind
B2
Abstract

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.

Claims (16)

1. A system for maintaining human pluripotent stem cells, comprising:

a chemically defined and xeno-free cell culture medium comprising from greater than zero to 3.9 ng/mL of basic fibroblast growth factor (bFGF), wherein the cell culture medium does not contain (1) insulin or an insulin substitute, and does not contain (2) transferrin or a transferrin substitute; and

a container having a substrate thereon, the substrate containing laminin-521 or laminin-511 for providing support to the human pluripotent stem cells.

2. The system of claim 1 , wherein the substrate also contains a cadherin.

3. The system of claim 1 , wherein the substrate comprises laminin-521 and wherein the amount of bFGF is 3.5 ng/mL or less.

4. The system of claim 1 , wherein the cell culture medium comprises from 0.5 to 3.5 ng/mL of bFGF.

5. The system of claim 1 , wherein the cell culture medium further comprises at least one additional growth factor, at least one trace mineral, and at least one lipid.

6. A chemically defined and xeno-free cell culture medium that provides nutrition to pluripotent stem cells, comprising from greater than zero to 3.9 ng/mL of basic fibroblast growth factor (bFGF), at least one additional growth factor, at least one trace mineral, and at least one lipid; wherein the cell culture medium does not contain (1) insulin or an insulin substitute, and does not contain (2) transferrin or a transferrin substitute.

7. The cell culture medium of claim 6 , comprising 3.5 ng/mL or less of bFGF.

8. The cell culture medium of claim 6 , comprising from 0.5 to 3.5 ng/mL of bFGF.

9. The cell culture medium of claim 6 , further comprising at least one inorganic salt.

10. The cell culture medium of claim 6 , further comprising at least one energy substrate.

11. The cell culture medium of claim 6 , further comprising at least one amino acid.

12. The cell culture medium of claim 6 , further comprising at least one vitamin.

13. The cell culture medium of claim 6 , further comprising at least one inorganic salt, at least one energy substrate, at least one amino acid, and at least one vitamin.

14. The cell culture medium of claim 6 , wherein the cell culture medium also does not contain any albumin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2012
From: TRYGGVASON, KARL; RODIN, SERGEY
To: BIOLAMINA AB
Reel/Frame 027722/0587 →
Continuity (7)
Provisional Application 61424273 · Dec 17, 2010
Provisional Application 61488353 · May 20, 2011
Provisional Application 61533063 · Sep 9, 2011
Provisional Application 61537940 · Sep 22, 2011
Provisional Application 61565380 · Nov 30, 2011
Provisional Application 61565849 · Dec 1, 2011
Related Publication 20120156782A1 · Jun 21, 2012
Cited By (2)
US 12,365,872 US 12,716,054